SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    T. Gruschwitz, M.-O. Grimm, Früherkennung in der Urologie, Der Onkologe, 2011, 18, 3, 243

    CrossRef

  2. 2
    Thomas J. Edwards, Andrew J. Dickinson, Jane Gosling, Paul D. McInerney, Salvatore Natale, John S. McGrath, Patient-specific risk of undetected malignant disease after investigation for haematuria, based on a 4-year follow-up, BJU International, 2011, 107, 2
  3. 3
    Alexandre R. Zlotta, Thierry Roumeguere, Cynthia Kuk, Sultan Alkhateeb, Sandrine Rorive, Anne Lemy, Theodorus H. van der Kwast, Neil E. Fleshner, Michael A.S. Jewett, Antonio Finelli, Claude Schulman, Yair Lotan, Shahrokh F. Shariat, Joelle Nortier, Select Screening in a Specific High-Risk Population of Patients Suggests a Stage Migration Toward Detection of Non–Muscle-Invasive Bladder Cancer, European Urology, 2011, 59, 6, 1026

    CrossRef

  4. 4
    Beate Pesch, Michael Nasterlack, Friedhelm Eberle, Nadine Bonberg, Dirk Taeger, Gabriele Leng, Gerhard Feil, Georg Johnen, Katta Ickstadt, Mattias Kluckert, Harald Wellhäußer, Arnllf Stenzl, Thomas Brüning, The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines, BJU International, 2011, 108, 4
  5. 5
    Michele Lodde, Christine Mian, Emanuela Trenti, Salvatore Palermo, Armin Pycha, Evi Comploj, The Use of Bladder Tumor Markers in the Clinical Practice, Current Urology, 2011, 5, 3, 113

    CrossRef

  6. 6
    Victoria L. Robinson, Michael Porter, Edward Messing, Yves Fradet, Ashish M. Kamat, Yair Lotan, BCAN Think Tank session 2: Molecular detection of bladder cancer: The path to progress, Urologic Oncology: Seminars and Original Investigations, 2010, 28, 3, 334

    CrossRef

  7. 7
    David M. Latini, Seth P. Lerner, Sally W. Wade, David W. Lee, Diane Z. Quale, Bladder Cancer Detection, Treatment and Outcomes: Opportunities and Challenges, Urology, 2010, 75, 2, 334

    CrossRef

  8. 8
    Yair Lotan, Shahrokh F. Shariat, Bernd J. Schmitz-Dräger, Marta Sanchez-Carbayo, Feliksas Jankevicius, Marco Racioppi, Sarah J.P. Minner, Brigitte Stöhr, Pier Francesco Bassi, H. Barton Grossman, Considerations on implementing diagnostic markers into clinical decision making in bladder cancer, Urologic Oncology: Seminars and Original Investigations, 2010, 28, 4, 441

    CrossRef

  9. 9
    C Giberti, F Gallo, M Schenone, A Genova, Early Results of Urothelial Carcinoma Screening in a Risk Population of Coke Workers: Urothelial Carcinoma among Coke Workers, Biomedical and Environmental Sciences, 2010, 23, 4, 300

    CrossRef

  10. 10
    Michael P. Porter, Examining the association between delay in diagnosis and decreased survival in bladder cancer, Cancer, 2010, 116, 22
  11. 11
    Ralph Madeb, Dragan Golijanin, Joy Knopf, Matthew Davis, Changyong Feng, Anne Fender, Laura Stephenson, Edward M. Messing, Long-term Outcome of Patients With a Negative Work-up for Asymptomatic Microhematuria, Urology, 2010, 75, 1, 20

    CrossRef

  12. 12
    C. Protzel, O.W. Hakenberg, Molekulare Marker in Diagnostik und Therapie des Urothelkarzinoms, Der Urologe, 2010, 49, 11, 1415

    CrossRef

  13. 13
    Deep Trivedi, Edward M. Messing, Reply, Urology, 2010, 75, 1, 25

    CrossRef

  14. You have free access to this content14
    Angela AG Van Tilborg, Chris H Bangma, Ellen C Zwarthoff, Bladder cancer biomarkers and their role in surveillance and screening, International Journal of Urology, 2009, 16, 1
  15. 15
    Yair Lotan, Keren Elias, Robert S. Svatek, Aditya Bagrodia, Geoffrey Nuss, Brett Moran, Arthur I. Sagalowsky, Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor Marker, The Journal of Urology, 2009, 182, 1, 52

    CrossRef

  16. 16
    Andrea B Apolo, Matthew Milowsky, Dean F Bajorin, Clinical states model for biomarkers in bladder cancer, Future Oncology, 2009, 5, 7, 977

    CrossRef

  17. 17
    Bas W.G. van Rhijn, Henk G. van der Poel, Theo H. van der Kwast, Cytology and Urinary Markers for the Diagnosis of Bladder Cancer, European Urology Supplements, 2009, 8, 7, 536

    CrossRef

  18. 18
    Jan J Koornstra, Marian JE Mourits, Rolf H Sijmons, Annemarie M Leliveld, Harry Hollema, Jan H Kleibeuker, Management of extracolonic tumours in patients with Lynch syndrome, The Lancet Oncology, 2009, 10, 4, 400

    CrossRef

  19. 19
    Samir P Shirodkar, Vinata B Lokeshwar, Potential new urinary markers in the early detection of bladder cancer, Current Opinion in Urology, 2009, 19, 5, 488

    CrossRef

  20. 20
    Jason R. Gee, David F. Jarrard, Reginald C. Bruskewitz, Timothy D. Moon, Sean P. Hedican, Glen E. Leverson, Stephen Y. Nakada, Edward M. Messing, Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin, BJU International, 2009, 103, 6
  21. 21
    Behfar Ehdaie, George J. Stukenborg, Dan Theodorescu, Renal Transplant Recipients and Patients With End Stage Renal Disease Present With More Advanced Bladder Cancer, The Journal of Urology, 2009, 182, 4, 1482

    CrossRef

  22. 22
    Emil Scosyrev, Katia Noyes, Changyong Feng, Edward Messing, Sex and racial differences in bladder cancer presentation and mortality in the US, Cancer, 2009, 115, 1
  23. 23
    Samir P Shirodkar, TA Kishore, Mark S Soloway, The risk and prophylactic management of bladder cancer after various forms of radiotherapy, Current Opinion in Urology, 2009, 19, 5, 500

    CrossRef

  24. 24
    Ralph Madeb, Dragan Golijanin, Katia Noyes, Susan Fisher, Judith J. Stephenson, Stacey R. Long, Joy Knopf, Gary H. Lyman, Edward M. Messing, Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine?, Cancer, 2009, 115, 12
  25. 25
    Andrew A. Renshaw, Cytology, 2009,

    CrossRef

  26. 26
    Samir P Shirodkar, Vinata B Lokeshwar, Bladder tumor markers: from hematuria to molecular diagnostics – where do we stand?, Expert Review of Anticancer Therapy, 2008, 8, 7, 1111

    CrossRef

  27. 27
    Arnulf Stenzl, Joerg Hennenlotter, David Schilling, Can we still afford bladder cancer?, Current Opinion in Urology, 2008, 18, 5, 488

    CrossRef

  28. 28
    Bas W.G. van Rhijn, Considerations on the Use of Urine Markers for Bladder Cancer, European Urology, 2008, 53, 5, 880

    CrossRef

  29. 29
    Hannes Steiner, Maria Bergmeister, Irmgard Verdorfer, Thomas Granig, Gregor Mikuz, Georg Bartsch, Brigitte Stoehr, Andrea Brunner, Early results of bladder-cancer screening in a high-risk population of heavy smokers, BJU International, 2008, 102, 3
  30. 30
    Robert S. Svatek, Yair Lotan, Is there a rationale for bladder cancer screening?, Current Urology Reports, 2008, 9, 5, 339

    CrossRef

  31. 31
    B. Diao, T. Amath, B. Fall, P.A. Fall, M.J. Diémé, N.N. Steevy, A.K. Ndoye, M. Ba, V. Mendes, B.A. Diagne, Les cancers de vessie au Sénégal : particularités épidémiologiques, cliniques et histologiques, Progrès en Urologie, 2008, 18, 7, 445

    CrossRef

  32. 32
    Mark Soloway, Possible malignancy after cytology analysis in a 45-year-old man, Current Urology Reports, 2008, 9, 3, 182

    CrossRef

  33. 33
    Sulma I. Mohammed, Munazzah Rahman, Proteomics and genomics of urinary bladder cancer, PROTEOMICS - Clinical Applications, 2008, 2, 9
  34. 34
    Michele Lodde, Yves Fradet, The detection of genetic markers of bladder cancer in urine and serum, Current Opinion in Urology, 2008, 18, 5, 499

    CrossRef

  35. 35
    James M Crawford, The origins of bladder cancer, Laboratory Investigation, 2008, 88, 7, 686

    CrossRef

  36. 36
    Huixian Liu, Michael J. Schwartz, David H. Hwang, Douglas S. Scherr, Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma, BJU International, 2008, 101, 7
  37. 37
    Badrinath Konety, Yair Lotan, Urothelial bladder cancer: biomarkers for detection and screening, BJU International, 2008, 102, 9b
  38. 38
    David C. Smith, James Montie, Howard Sandler, Abeloff's Clinical Oncology, 2008,

    CrossRef

  39. 39
    Edward M. Messing, Ralph Madeb, Author reply, Cancer, 2007, 109, 9
  40. 40
    Alonso Alvarez, Vinata B Lokeshwar, Bladder cancer biomarkers: current developments and future implementation, Current Opinion in Urology, 2007, 17, 5, 341

    CrossRef

  41. 41
    Yair Lotan, Robert S Svatek, Cost–effectiveness of bladder cancer screening, Expert Review of Pharmacoeconomics & Outcomes Research, 2007, 7, 6, 627

    CrossRef

  42. 42
    Ralph Madeb, Dragan Golijanin, Joy Knopf, Edward M Messing, Current state of screening for bladder cancer, Expert Review of Anticancer Therapy, 2007, 7, 7, 981

    CrossRef

  43. 43
    How useful is bladder cancer screening?, Nature Clinical Practice Urology, 2007, 4, 2, 63

    CrossRef

  44. 44
    Ralph Madeb, Edward M. Messing, Long-term outcome of home dipstick testing for hematuria, World Journal of Urology, 2007, 26, 1, 19

    CrossRef

  45. 45
    Tommaso Cai, Riccardo Bartoletti, Long-term outcome of hematuria home screening for bladder cancer in men, Cancer, 2007, 109, 9
  46. 46
    Edward Messing, Markers of detection, Urologic Oncology: Seminars and Original Investigations, 2007, 25, 4, 344

    CrossRef

  47. 47
    Edward M. Messing, Re: Should We Screen for Bladder Cancer in a High-Risk Population? A Cost Per Life-Year Saved Analysis, European Urology, 2007, 51, 4, 1140

    CrossRef

  48. 48
    Yair Lotan, Robert S. Svatek, Núria Malats, Screening for bladder cancer: a perspective, World Journal of Urology, 2007, 26, 1, 13

    CrossRef

  49. 49
    Edmund Chiong, Kris E. Gaston, H. Barton Grossman, Urinary markers in screening patients with hematuria, World Journal of Urology, 2007, 26, 1, 25

    CrossRef